Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PC1 | P35575 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995423 | 0.85 | G6PC1 (0.46) | G6PC1HRH4HRH3AGERMTNR1A | |
| SCHEMBL3247714 | 0.76 | G6PC1 (0.51) | G6PC1HRH4HRH3AGERMTNR1A | |
| SCHEMBL5993497 | 0.76 | LMNA (0.43) | G6PC1TRPM8KDM4EMEN1ALDH1A1 | |
| SCHEMBL10891206 | 0.73 | G6PC1 (0.50) | G6PC1HRH4HRH3AGERMTNR1A | |
| SCHEMBL3252099 | 0.71 | LMNA (0.46) | G6PC1TRPM8KDM4EMEN1ALDH1A1 | |
| SCHEMBL7603670 | 0.71 | HRH3 (0.73) | G6PC1HRH4HRH3AGERKDM4E | |
| SCHEMBL7885548 | 0.70 | G6PC1 (0.54) | G6PC1HRH4HRH3AGERMTNR1A | |
| SCHEMBL515999 | 0.70 | G6PC1 (0.54) | G6PC1HRH4HRH3AGERMTNR1A | |
| SCHEMBL11115148 | 0.70 | SLC6A2 (0.56) | G6PC1HRH4HRH3AGERMTNR1A | |
| SCHEMBL10709827 | 0.70 | SLC6A2 (0.56) | G6PC1HRH4HRH3AGERMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995285-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050267215-A1 | ATP binding cassette transporter 1 (ABCA-1); increases high density lipoprotein (HDL) levels; use treating coronary artery disease; N-phenyl-N-(2-hydroxy-cyclohexyl)-2-(1,3,3-trimethyl-bicyclo[2.2.1]hept-2-ylamino)acetamide for example | CV THERAPEUTICS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-6713650-B2 | ELEVATES ATP BINDING CASSETTE TRANSPORTER 1 EXPRESSION THEREBY INCREASING EFFLUX OF CHOLESTEROL FROM CELLS BY ACTIVE TRANSFER INTO HIGH DENSITY LIPOPROTEINS | CV THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1377283-A2 | COMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003103651-A1 | COMPOUNDS OF THE FORMU;A R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CAD OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20020082257-A1 | ABCA-1 Elevating compounds | CV THERAPEUTICS, INC. | 2002-06-27 | — | — | US | disclosed |
| WO-2002046141-A2 | COUMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267215-A1 | ATP binding cassette transporter 1 (ABCA-1); increases high density lipoprotein (HDL) levels; use treating coronary artery disease; N-phenyl-N-(2-hydroxy-cyclohexyl)-2-(1,3,3-trimethyl-bicyclo[2.2.1]hept-2-ylamino)acetamide for example | ABCD3, ABCF1, ABCC2 | G6PC1 2682/4885HRH4 1462/4885HRH3 1610/4885 |
| US-20020082257-A1 | ABCA-1 Elevating compounds | ABCD3, ABCE1, ABCB4 | G6PC1 1086/4885HRH4 4305/4885HRH3 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.